[英文调查报告书] 制药企业分析：Novartis

Abstract

Novartis was created in 1996 from the merger of the Swiss companies, Ciba and Sandoz. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

Following the merger of Ciba and Sandoz, the spin-off of the Agribusiness sector and the sale of the remaining activities of the Industry division, Novartis has become a leading company in the life sciences field. Novartis is currently organised into the three divisions of Pharmaceuticals, Consumer Health and Sandoz. A fourth division, Vaccines & Diagnostics, will be created after the acquisition of Chiron Corporation.

Current Growth Drivers

These include: Diovan (valsartan), Glivec/Gleevec (imatinib), Zelmac/Zelnorm (tegaserod), Femara (letrozole) and Zometa (zoledronate).

Key Late-Phase Products Reaching the Market

Lucentis (ranibizumab) is currently filed for age-related macular degeneration.
Two cardiovascular products currently filed have the potential to become mega-blockbusters: Rasilez (aliskiren) for the treatment of hypertension; and Galvus (vildagliptin), indicated for Type II diabetes.

Principal Operating Results

EXECUTIVE SUMMARY

Introduction
- Current Growth Drivers
- Key Late-Phase Products Reaching the Market
- Key Late-Stage Products
Financial Performance 2005
- Sales and Market Position
- Income
- Expenditure
  - Capital Expenditure
  - Capital Expenditure By Business Area
  - Capital Expenditure By Geographical Area
  - R&D Expenditure
  - Research And Development Expenditure By Business Area
- Divisional Performance
  - Sales By Business Area
  - Operating Income By Business Area
- Geographic Performance
  - Operating Income By Geographical Area
  - Total Assets By Destination
  - Sales By Destination
Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Employees
  - Employees By Business Area (Year End)
  - Employees By Geographical Area (Year End)
Product / R&D Overview
- Key Products
  - Recent Product Launches
  - Recent Product Approvals
- R&D Strategy
  - Key R&D Projects
- R&D Pipeline Overview
  - Discontinued R&D projects
- Sales Forecasts
Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

R&D Pipeline
Cardiovascular - Products
- Major Launched Products
- Diovan/Co-Diovan
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Further Development
  - Licensees
  - Competitor Products
  - Sales Forecast
  - Clinical Trial Results - Val-HeFT trial
  - VALIANT trial
  - VALUE trial
- Lescol
  - Sales
  - Key Markets/Indications
  - Further Development
  - Patents/Licensees
  - Competitor Products
  - Sales Forecast
- Lotrel
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Further Development
  - Competitor Products
  - Sales Forecast
Cardiovascular and Metabolism - R&D
- APP018
- Exforge
  - Clinical Trial Results
- Galvus
  - Mode of Action
  - Development Status
  - Clinical Trial Results
- LBM642
- Rasilez
  - Mode of Action
  - Development Status
  - Clinical Trial Results
- VNP489
Cardiovascular and Metabolism - Summary
Oncology / Haematology - Products
- Major Launched Products
- Exjade
- Femara
  - Sales
  - Key Markets/Indications
  - Further Development
  - Sales Forecast
  - Clinical Trial Results
- Glivec/Gleevec
  - Sales
  - Key Markets/Indications
  - Further Development
  - Competitor Products
  - Generic competition
  - Sales Forecast
  - Clinical Trial Results - CML
  - Clinical Trial Results - GIST
  - Clinical Trial Results - ALL
  - Clinical Trial Results - HES
- Sandostatin
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Generic Competition
  - Sales Forecast
- Zometa/Aclasta
  - Sales
  - Key Markets/Indications
  - Further Development
  - Safety Issues
  - Sales Forecast
  - Clinical Trial Results - Paget's Disease
Oncology / Hematology - R&D
- AEE788
- ABJ879
- Gimatecan (LBQ707)
- LBH589
- Tasigna
  - Clinical Trial Results
- Midostaurin
- Pasireotide (SOM230)
- Patupilone
- Vatalanib (PTK787)
  - Development Status
  - Clinical Trial Results
Oncology / Haematology - Summary
- Growth Potential
- Limiting Factors
Rheumatology, Bone and Hormone Replacement Therapy - Products
- Major Launched Products
- Miacalcic/Miacalcin
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Generic Competition
  - Competitor Products
  - Sales Forecast
Rheumatology, Bone and Hormone Replacement Therapy - R&D
- Balicatib
- Prexige
  - Clinical Trial Results
Rheumatology Bone and Hormone Replacement Therapy - Summary
Central Nervous System - Products
- Major Launched Products
- Comtan
  - Sales
  - Key Markets/Indications
  - Further Development
- Exelon
  - Sales
  - Key Markets/Indications
  - Further Development
  - Sales Forecast
  - Clinical Trial Results
- Focalin
  - Key Markets/Indications
- Ritalin
  - Competitor Products
  - Lawsuits
  - Generic Competition
  - Clinical Trial Results - Ritalin LA versus Concerta
- Stalevo
  - Further Development
- Tegretol
  - Sales
  - Key Markets/Indications
  - Generic Competition
  - Sales Forecast
- Trileptal
  - Sales
  - Key Markets/Indications
  - Safety Issues
  - Sales Forecast
Central Nervous System - R&D
- Fingolimod
  - Clinical Trial Results
- Licarbazepine (LIC477)
- SAB378
- Valdoxan
- XBD173 (AC-5216)
Central Nervous System - Summary
Respiratory / Dermatology - Products
- Elidel
  - Sales
  - Key Markets/Indications
  - Further Development
  - Safety Issues
  - Competitor Products
  - Sales Forecast
- Foradil
  - Sales
  - Key Markets/Indications
  - Safety Issues
  - Further Development
  - Competitor Products
- Lamisil
  - Sales
  - Key Markets/Indications
  - Further Development
  - Competitor Products
  - Generic Competition
  - Sales Forecast
- Xolair
  - Key Markets/Indications
  - Further development
  - Clinical Trial Results
Respiratory / Dermatology- R&D
- Indacaterol
  - Clinical Trial Results
- NVA237
Respiratory / Dermatology - Summary
Autoimmunity & Transplantation - Products
- Major Launched Products
- Certican
  - Key Markets/Indications
  - Further Development
  - Lawsuit
  - Clinical Trial Results
  - Everolimus versus azathioprine
  - Everolimus versus MMF
- Sandimmun/Neoral
  - Sales
  - Key Markets/Indications
  - Patents/Generic Competition/Lawsuits
  - Sales Forecast
Autoimmunity & Transplantation / Immunology R&D
- AEB071
Autoimmunity & Transplantation - Summary
Ophthalmics - Products
- Major Launched Products
- Visudyne
  - Sales
  - Key Markets/Indications
  - Further Development
  - Lawsuits
  - Sales Forecast
Ophthalmics - R&D
- Lucentis
  - Key Markets/Indications
  - Further Development
  - Clinical Trial Results
- Rebamipide
Ophthalmics - Summary
Gastrointestinal - Products
- Major Launched Products
- Zelmac/Zelnorm (HTF919)
  - Sales
  - Key Markets/Indications
  - Further Development
  - Sales Forecast
Gastrointestinal - R&D
- CS-526 (R-105266)
Gastrointestinal - Summary
Infectious Diseases - Products
- Major Launched Products
- Famvir/Denavir
  - Mode of Action
  - Sales
  - Key Markets/Indications
  - Patents
  - Sales Forecast
- Voltaren/Cataflam
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Generic Competition
  - Sales Forecast
Infectious Diseases - R&D
- ANA975
  - Clinical Trial Results
- RSV604
- Sebivo
  - Clinical Trial Results
- VAG624
- Valopicitabine
  - Clinical Trial Results
- Valtorcitabine
Infectious Diseases - Summary

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2005

APPENDIX 2 - KEY AGREE MENTS

Accelrys Inc/Pharmacopeia Inc
- 3rd October 1995
- 9th January 2003
Ablynx
- 18th January 2006
Ajinomoto Co Inc
- 19th January 1994
Alfacell Corporation
- 21st July 2005
Allergan
- 18th March 1993
- 19th April 2005
Alnylam Pharmaceuticals
- 7th September 2005
- 21st February 2006
ALZA Corporation
Anadys Pharmaceuticals Inc
- 2nd June 2005
Arrow Therapeutics Ltd
- 30th June 2005
Astex Therapeutics Ltd
- 6th December 2005
AstraZeneca
- June 1993
Argenta Discovery Ltd
- 24th January 2005
Avanir Pharmaceuticals Corporation
- 28th April 2005
Avera Pharmaceuticals Inc
- 28th October 2003
Avalon Pharmaceuticals
- 13th September 2005
Barrier Therapeutics
- 15th March 2006
Bausch & Lomb Inc
- 10th February 2006
Broad Institute / Harvard University
- 27th October 2004
Bristol-Myers Squibb
- 3rd June 1997
- 28th March 2001
Britannia Pharmaceuticals Ltd
- 22nd September 2003
Biovail Corporation
- 19th May 2006
Celgene Corporation
- 26th April 2000
- 18th January 2001
Cell Genesys Inc
- 23rd July 2003
- August 2004
Cerimon Pharmaceuticals Inc
- 21st February 2006
Chiron Corporation
- November 1995
- December 1995
- November 1996
- 22nd April 2003
- 3rd April 2006
Chugai
- February 1995
Conor Medsystems Inc
- 15th March 2005
- 16th March 2006
Cytos Biotechnology AG
- 28th April 2003
- 3rd February 2004
- 14th February 2006
Cytopia Ltd
- 4th June 2006
Daiichi Sankyo
- 8th October 2003
Dainippon Sumitomo Pharma
- 12th February 2002
Eisai
- 6th February 2004
Elan Corporation plc
- 14th January 1998
- 1991
Emisphere Technologies Inc
- February 2000
- February 2000
- 1st December 2004
- 23rd September 2004
- 9th January 2006
- March 2006
ESBATech AG
- 31st March 2005
FFF Enterprises Inc
- 27th April 2006
Galapagos Genomics NV
- 6th July 2005
Genelabs Technologies
- 5th June 2006
Human Genome Sciences (HGS)
- 6th June 2006
Idera Pharmaceuticals Inc
- 1st June 2005
Idenix Pharmaceuticals Inc
- 9th May 2003
- 29th March 2006
Immusol Incorporated
- 1st October 2001
- 16th August 2005
Infinity Pharmaceuticals Inc
- 13th February 2003
- 5th January 2005
- 6th March 2006
Intercell AG
- 13th June 2006
IVAX Corporation
- 17th January 2003
Kalobios Inc
- 31st May 2006
Kowa Company Ltd/Nissan Chemical Industries Ltd
- 23rd April 2001
Kyorin Pharmaceutical Co Ltd
- 16th February 2006
Meda AB
- 20th January 2005
Medivir AB
- 13th August 2004
Merck KGaA
- 8th August 2000
Mitsubishi Pharma Corporation
- 24th September 1997
MorphoSys AG
- 19th May 2004
- 8th August 2005
Myogen Inc
- 13th October 2003
- 26th May 2005
Noven Pharmaceuticals Inc
- 2nd August 2001
Ono Pharmaceutical Co Ltd
- 12th December 2005
Orion Corporation
February 1996 agreement
- 7th September 2000
Otsuka
- 12th January 1999
- 7th February 2005
PDL BioPharma Inc
- April 1993
- 11th July 2002
QLT Inc
- 6th February 1995
- 4th April 1995
- 17th April 2000
- 30th October 2000
- 23rd July 2003
Reliant Pharmaceuticals Inc
- 11th April 2005
Saegis Pharmaceuticals Inc
- 6th January 2004
sanofi-aventis
- February 1994
- 12th September 1997
- 29th June 1998
- 5th October 1999
- 6th November 2000
Schering AG
- 25th January 2005
Schering-Plough
- 10th April 2003
- 30th October 2002
Scripps Research Institute
December 1992
Senju Pharmaceutical Co Ltd
- 9th November 2005
Servier
- 29th March 2006
Sigma-Tau
- 6th November 2003
SGX Pharmaceuticals Inc
- 27th March 2006
SkyePharma PLC
- 17th November 1998
- 2nd December 2003
Tanabe Seiyaku Co Ltd
- In July 1993
- 18th October 2002
Tanox Biosystems Inc/Genentech Inc
- 15th May 1990
- 25th June 2003
- 26th February 2004
- 23rd January 2006
Valley Forge Pharmaceuticals Inc
- 8th January 2003
Vectura Group plc/Arakis Ltd
- 13th April 2005
Vernalis plc
- 19th December 2003
- 9th August 2004
- 19th December 2005
Vertex Pharmaceuticals Inc
- 9th May 2000
- 3rd February 2004
- 10th November 2004
Vicuron Pharmaceuticals Inc
- 27th March 2003
Xenon Pharmaceuticals Inc
- 20th September 2004
Xenogen Corporation
- 28th January 1999
- 1st August 2000
- 7th December 2005

制药企业分析报告：Novartis

Novartis: Performance, Products, Pipeline, Potential

Abstract

Table of Contents

EXECUTIVE SUMMARY

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

APPENDIX 1 - FINANCIAL PERFORMANCE

APPENDIX 2 - KEY AGREE MENTS

APPENDIX 3 - INFRASTRUCTURE

APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

APPENDIX 5 - PRODUCT INDEX